School of Medical Technology, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China; Key Laboratory of Bone Marrow Stem Cell, Xuzhou, Jiangsu, China; Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
J Lipid Res. 2022 Oct;63(10):100273. doi: 10.1016/j.jlr.2022.100273. Epub 2022 Sep 7.
Liposomes are the most widely used nanocarrier platform for the delivery of therapeutic and diagnostic agents, and a number of liposomes have been approved for use in clinical practice. After systemic administration, most liposomes are cleared by macrophages in the mononuclear phagocyte system, such as the liver and bone marrow (BM). However, the majority of studies have focused on investigating the therapeutic results of liposomal drugs, and too few studies have evaluated the potential side effects of empty nanocarriers on the functions of macrophages in the mononuclear phagocyte system. Here, we evaluate the potential effects of empty liposomes on the functions of BM niche macrophages. Following liposome administration, we observed lipid droplet (LD) accumulation in cultured primary macrophages and BM niche macrophages. We found that these LD-accumulating macrophages, similar to foam cells, exhibited increased expression of inflammatory cytokines, such as IL-1β and IL-6. We further provided evidence that liposome deposition and degradation induced LD biogenesis on the endoplasmic reticulum membrane and subsequently disturbed endoplasmic reticulum homeostasis and activated the inositol-requiring transmembrane kinase/endoribonuclease 1α/NF-κB signaling pathway, which is responsible for the inflammatory activation of macrophages after liposome engulfment. Finally, we also showed the side effects of dysfunctional BM niche macrophages on hematopoiesis in mice, such as the promotion of myeloid-biased output and impairment of erythropoiesis. This study not only draws attention to the safety of liposomal drugs in clinical practice but also provides new directions for the design of lipid-based drug carriers in preclinical studies.
脂质体是最广泛应用于治疗剂和诊断剂传递的纳米载体平台,许多脂质体已被批准用于临床实践。在系统给药后,大多数脂质体被单核吞噬细胞系统中的巨噬细胞清除,如肝脏和骨髓(BM)。然而,大多数研究都集中在研究脂质体药物的治疗效果上,很少有研究评估空纳米载体对单核吞噬细胞系统中巨噬细胞功能的潜在副作用。在这里,我们评估了空脂质体对 BM 龛位巨噬细胞功能的潜在影响。在给予脂质体后,我们观察到培养的原代巨噬细胞和 BM 龛位巨噬细胞中脂质滴(LD)的积累。我们发现,这些积累 LD 的巨噬细胞与泡沫细胞类似,表现出炎症细胞因子(如 IL-1β 和 IL-6)的表达增加。我们进一步提供了证据表明,脂质体的沉积和降解诱导内质网膜上 LD 的生物发生,从而扰乱内质网的稳态并激活肌醇需求跨膜激酶/内切核糖核酸酶 1α/NF-κB 信号通路,该通路负责脂质体吞噬后巨噬细胞的炎症激活。最后,我们还表明功能失调的 BM 龛位巨噬细胞对小鼠造血的副作用,如促进髓系偏向输出和损害红细胞生成。这项研究不仅引起了人们对临床实践中脂质体药物安全性的关注,也为临床前研究中基于脂质的药物载体的设计提供了新的方向。